December 16, 2022
After nearly a decade of litigation, an Illinois federal judge has signed off on a $15 million settlement ending indirect purchasers' claims that they overpaid for the prescription painkiller Opana ER due to a pay-for-delay deal struck between Endo Pharmaceuticals and Impax.
November 04, 2022
The attorneys who secured a $145 million settlement for direct purchasers of Endo Pharmaceuticals's Opana ER who said they overpaid generic-drug maker Impax Labs for the prescription painkiller because of a pay-for-delay deal will walk away from the litigation with more than $50 million for their trouble.
September 20, 2022
Attorneys for direct purchasers of Opana ER, including Value Drug Co. and Meijer Inc., asked an Illinois federal judge Monday for a fee award of $50 million after the class reached a $145 million settlement with generic-drug maker Impax Labs to end nearly eight years of litigation over pay-for-delay allegations.
July 20, 2022
Direct purchasers of Opana ER including Value Drug Co. and Meijer Inc. told an Illinois federal judge Tuesday they had reached a $145 million settlement with generic-drug maker Impax Labs to end nearly eight years of "intense" litigation over pay-for-delay allegations that Endo Pharmaceuticals beat at trial.
July 01, 2022
An Illinois jury sided with Endo Pharmaceuticals on Friday over allegations that it struck an unlawful settlement with Impax Laboratories to delay a generic version of Endo's Opana ER painkiller, finding the deal did more to boost competition than stifle it.
June 30, 2022
Opana ER buyers told an Illinois federal jury Thursday that Endo Pharmaceuticals raked in profits by striking an unlawful settlement to delay a generic competitor for its opioid, saying the deal forced them to pay higher prices longer than they should have.
June 24, 2022
Well into an antitrust trial over an alleged pay-for-delay scheme surrounding Endo Pharmaceuticals' Opana ER painkiller, a group of major retail chains cut a midtrial settlement Friday with Impax Laboratories, one of the defendants in the wide-ranging case.
June 14, 2022
In an ongoing antitrust trial over an alleged pay-for-delay scheme surrounding Endo Pharmaceuticals' Opana ER painkiller, a former Impax Laboratories executive testified Tuesday that the generic-drug maker had always pushed to bring its version to market as soon as possible.
February 28, 2022
Buyers who say they overpaid for the prescription painkiller Opana ER want their pay-for-delay fight with Endo Pharmaceuticals and Impax Laboratories sliced into three separate trials, the buyers told an Illinois federal court Friday.
July 14, 2021
A Seventh Circuit panel on Tuesday sent a class certification decision back for partial reconsideration because an Illinois federal judge didn't analyze the potential for uninjured members winding up in the class of Opana ER end-payors accusing Endo Pharmaceuticals of cutting an anti-competitive pay-for-delay deal protecting the painkiller.